Gapping up
In reaction to earnings/guidance:
- OSUR +18.9%, TTD +11%, TRIP +9.4%, ABNB +9.4%, NU +9.2%, ADPT +6.6%, ADI +6%, ALVR +4.9%, HLF +4.3%, CEVA +3.9%, CRK +3.4%, ANDE +3.4%, SFL +3%, WIRE +2.5%, GNRC +2.2%, DNUT +1.7%, CAL +1.7%, HCSG +1.4%, CHH +1.2%, ADC +1.1%, BIIB +1%
Other news:
- EBS +9.4% (divests Travel Health Business to Bavarian Nordic for Up To $380 mln)
- ADI +6% (increases dividend)
- KNTE +5% (FDA grants Fast Track designation for KIN-3248)
- RBBN +3.1% (Bharti Airtel selects co to build its new high-speed transport network)
- LPX +2.7% (Berkshire Hathaway / Warren Buffett discloses increased position in 13F filing)
- GPI +2.5% (increases dividend)
- PARA +2.4% (Berkshire Hathaway / Warren Buffett discloses increased position in 13F filing)
- QGEN +2.1% (announces EU certification of QuantiFERON-TB Gold Plus)
- CNCE +1.9% (announces that, after a recent review of deuruxolitinib clinical data by the U.S. FDA, the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation)
- EXPE +1.6% (in sympathy with strong ABNB earnings)
- BKNG +1.1% (in sympathy with strong ABNB earnings)
Analyst comments:
- TSLA +2.2% (initiated with an Overweight at Barclays)